CohBar, Inc. (CWBR)
OTCMKTS: CWBR · Delayed Price · USD
0.241
0.00 (0.00%)
Jul 19, 2024, 3:50 PM EDT - Market open
CohBar Employees
As of December 31, 2022, CohBar had 10 total employees, including 9 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
10
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,234,759
Market Cap
699.12K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
CWBR News
- 8 months ago - CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K) - Business Wire
- 10 months ago - COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR - Business Wire
- 1 year ago - CohBar Reports Second Quarter 2023 Financial Results - GlobeNewsWire
- 1 year ago - Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) - GlobeNewsWire
- 1 year ago - Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 1 year ago - Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc. - PRNewsWire
- 1 year ago - CWBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of CohBar, Inc. Is Fair to Shareholders - Business Wire
- 1 year ago - CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy - GlobeNewsWire